Cargando…

A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence

BACKGROUND: With the addition of surgical interventions to current medicinal treatments, it is increasingly challenging for clinicians to rationally choose among the various options for treating patients with apparent treatment-resistant hypertension (ATRHTN). This study aims to establish the compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Makai, Peter, IntHout, Joanna, Deinum, Jaap, Jenniskens, Kevin, Wilt, Gert Jan van der
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515781/
https://www.ncbi.nlm.nih.gov/pubmed/28275946
http://dx.doi.org/10.1007/s11606-017-4000-7
_version_ 1783251032845844480
author Makai, Peter
IntHout, Joanna
Deinum, Jaap
Jenniskens, Kevin
Wilt, Gert Jan van der
author_facet Makai, Peter
IntHout, Joanna
Deinum, Jaap
Jenniskens, Kevin
Wilt, Gert Jan van der
author_sort Makai, Peter
collection PubMed
description BACKGROUND: With the addition of surgical interventions to current medicinal treatments, it is increasingly challenging for clinicians to rationally choose among the various options for treating patients with apparent treatment-resistant hypertension (ATRHTN). This study aims to establish the comparative effectiveness of mineralocorticoid receptor antagonists (MRA), renal denervation (RDN), darusentan and central arteriovenous anastomosis (CAA) for patients with ATRHTN by performing a network meta-analysis. METHODS: Data Sources: Studies from recent meta-analyses for RDN and placebo effect were supplemented with a systematic search for MRAs in ATRHTN in the Pubmed, EMBASE, CINAHL and Cochrane databases through November 2016. Study Selection: Randomized controlled trials comparing treatment options for patients with ATRHTN. Data Extraction and Synthesis: Data were extracted using predefined data extraction forms, including the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. A Bayesian random effects model was used to conduct a network meta-analysis. Spironolactone was used as the main comparator. Main Outcomes and Measures: Reduction in 24-h ambulatory blood pressure measurement (ABPM). RESULTS: Twenty articles met our inclusion criteria, and seven treatment alternatives were compared. Compared to MRA, CAA had the highest probability of being more effective, further reducing 24-h SBP (−4.8 mmHg [−13.0, 3.7]) and 24-h DBP (−9.7 mmHg [−18, -0.63]). This difference is likely to be clinically meaningful, with a probability of 78 and 96% at a threshold of a 2-mmHg reduction in blood pressure. CONCLUSIONS: When compared to MRA as anchor, darusentan, CAA and RDN are not more effective in achieving a clinically significant reduction in ambulatory blood pressure in individuals with apparent treatment-resistant hypertension. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11606-017-4000-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5515781
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-55157812017-08-01 A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence Makai, Peter IntHout, Joanna Deinum, Jaap Jenniskens, Kevin Wilt, Gert Jan van der J Gen Intern Med Review Paper BACKGROUND: With the addition of surgical interventions to current medicinal treatments, it is increasingly challenging for clinicians to rationally choose among the various options for treating patients with apparent treatment-resistant hypertension (ATRHTN). This study aims to establish the comparative effectiveness of mineralocorticoid receptor antagonists (MRA), renal denervation (RDN), darusentan and central arteriovenous anastomosis (CAA) for patients with ATRHTN by performing a network meta-analysis. METHODS: Data Sources: Studies from recent meta-analyses for RDN and placebo effect were supplemented with a systematic search for MRAs in ATRHTN in the Pubmed, EMBASE, CINAHL and Cochrane databases through November 2016. Study Selection: Randomized controlled trials comparing treatment options for patients with ATRHTN. Data Extraction and Synthesis: Data were extracted using predefined data extraction forms, including the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. A Bayesian random effects model was used to conduct a network meta-analysis. Spironolactone was used as the main comparator. Main Outcomes and Measures: Reduction in 24-h ambulatory blood pressure measurement (ABPM). RESULTS: Twenty articles met our inclusion criteria, and seven treatment alternatives were compared. Compared to MRA, CAA had the highest probability of being more effective, further reducing 24-h SBP (−4.8 mmHg [−13.0, 3.7]) and 24-h DBP (−9.7 mmHg [−18, -0.63]). This difference is likely to be clinically meaningful, with a probability of 78 and 96% at a threshold of a 2-mmHg reduction in blood pressure. CONCLUSIONS: When compared to MRA as anchor, darusentan, CAA and RDN are not more effective in achieving a clinically significant reduction in ambulatory blood pressure in individuals with apparent treatment-resistant hypertension. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11606-017-4000-7) contains supplementary material, which is available to authorized users. Springer US 2017-03-08 2017-08 /pmc/articles/PMC5515781/ /pubmed/28275946 http://dx.doi.org/10.1007/s11606-017-4000-7 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Paper
Makai, Peter
IntHout, Joanna
Deinum, Jaap
Jenniskens, Kevin
Wilt, Gert Jan van der
A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence
title A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence
title_full A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence
title_fullStr A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence
title_full_unstemmed A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence
title_short A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence
title_sort network meta-analysis of clinical management strategies for treatment-resistant hypertension: making optimal use of the evidence
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515781/
https://www.ncbi.nlm.nih.gov/pubmed/28275946
http://dx.doi.org/10.1007/s11606-017-4000-7
work_keys_str_mv AT makaipeter anetworkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence
AT inthoutjoanna anetworkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence
AT deinumjaap anetworkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence
AT jenniskenskevin anetworkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence
AT wiltgertjanvander anetworkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence
AT makaipeter networkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence
AT inthoutjoanna networkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence
AT deinumjaap networkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence
AT jenniskenskevin networkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence
AT wiltgertjanvander networkmetaanalysisofclinicalmanagementstrategiesfortreatmentresistanthypertensionmakingoptimaluseoftheevidence